/stocks — the workspaceLOADING

SRPT · All filings · Read this filing

What changed 10-Q

Item 5. Other Information

2022-11-02 compared with 2022-08-02 · 24 added, 8 removed, 39 unchanged (45% of the section changed)

11 unchanged sentences

1 to the Amended and Restated Bylaws.

Amendment No.

2 to the Sarepta Therapeutics, Inc.

2018 Equity Incentive Plan

Amendment no.

9 dated March 23, 2022 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F.

Hoffman-La Roche Ltd, dated December 21, 2019

Indenture, dated as of September 16, 2022, by and between Sarepta Therapeutics, Inc.

Bank Trust Company, National Association (including the form of the 1.250% Convertible Senior Note due 2027).

Base Call Option Transaction Confirmation, dated as of September 13, 2022, between Sarepta Therapeutics, Inc.

and Barclays Bank PLC.

Base Call Option Transaction Confirmation, dated as of September 13, 2022, between Sarepta Therapeutics, Inc.

and Goldman Sachs & Co.

Base Call Option Transaction Confirmation, dated as of September 13, 2022, between Sarepta Therapeutics, Inc.

and Mizuho Markets Americas LLC.

Base Call Option Transaction Confirmation, dated as of September 13, 2022, between Sarepta Therapeutics, Inc.

and Morgan Stanley & Co.

Base Call Option Transaction Confirmation, dated as of September 13, 2022, between Sarepta Therapeutics, Inc.

and RBC Capital Markets, LLC.

Additional Call Option Transaction Confirmation, dated as of S eptember 14, 2022 between Sarepta Therapeutics, Inc.

and Barclays Bank PLC.

Additional Call Option Transaction Confirmation, dated as of September 14, 2022 between Sarepta Therapeutics, Inc.

and Goldman Sachs & Co.

Additional Call Option Transaction Confirmation, dated as of September 14, 2022 between Sarepta Therapeutics, Inc.

and Mizuho Markets Americas LLC.

Additional Call Option Transaction Confirmation, dated as of September 14, 2022 between Sarepta Therapeutics, Inc.

and Morgan Stanley & Co.

Additional Call Option Transaction Confirmation, dated as of September 14, 2022 between Sarepta Therapeutics, Inc.

and RBC Capital markets, LLC.

Certification of the Company’s Principal Executive Officer, Douglas S.

20 unchanged sentences

SAREPTA THERAPEUTICS, INC.

August 2, 2022

November 2, 2022

/s/ DOUGLAS S.

1 unchanged sentence

(Principal Executive Officer)

August 2, 2022

November 2, 2022

Executive Vice President, Chief Financial Officer

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.